Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software
- PMID: 37745656
- PMCID: PMC10516298
- DOI: 10.3389/fneur.2023.1243594
Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software
Abstract
A growing body of evidence supports the link between eye movement anomalies and brain health. Indeed, the oculomotor system is composed of a diverse network of cortical and subcortical structures and circuits that are susceptible to a variety of degenerative processes. Here we show preliminary findings from the baseline measurements of an ongoing longitudinal cohort study in MS participants, designed to determine if disease and cognitive status can be estimated and tracked with high accuracy based on eye movement parameters alone. Using a novel gaze-tracking technology that can reliably and accurately track eye movements with good precision without the need for infrared cameras, using only an iPad Pro embedded camera, we show in this cross-sectional study that several eye movement parameters significantly correlated with clinical outcome measures of interest. Eye movement parameters were extracted from fixation, pro-saccade, anti-saccade, and smooth pursuit visual tasks, whereas the clinical outcome measures were the scores of several disease assessment tools and standard cognitive tests such as the Expanded Disability Status Scale (EDSS), Brief International Cognitive Assessment for MS (BICAMS), the Multiple Sclerosis Functional Composite (MSFC) and the Symbol Digit Modalities Test (SDMT). Furthermore, partial least squares regression analyses show that a small set of oculomotor parameters can explain up to 84% of the variance of the clinical outcome measures. Taken together, these findings not only replicate previously known associations between eye movement parameters and clinical scores, this time using a novel mobile-based technology, but also the notion that interrogating the oculomotor system with a novel eye-tracking technology can inform us of disease severity, as well as the cognitive status of MS participants.
Keywords: BICAMS; EDSS; MSFC; SDMT; digital biomarker; machine learning; mobile eye-tracker; multiple scleorsis.
Copyright © 2023 de Villers-Sidani, Voss, Bastien, Cisneros-Franco, Hussein, Mayo, Koch, Drouin-Picaro, Blanchette, Guitton and Giacomini.
Conflict of interest statement
ÉV-S was a co-founder of Innodem Neurosciences, which developed the Eye-Tracking Neurological Assessment (ETNA™) technology used in this study. PV and AD-P has ownership options in Innodem Neurosciences. JC-F was a part-time employee of Innodem Neurosciences and NK was a research intern at Innodem Neurosciences. DG was an unpaid consultant of Innodem Neurosciences. NB, SH, and FB were employees of Novartis Pharmaceuticals Canada Inc. PG was a paid medical and scientific advisor with Innodem Neurosciences and has stock options in Innodem Neurosciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Correlations Between Oculometric Measures and Traditional Clinical Assessments in Multiple Sclerosis.Mult Scler Relat Disord. 2025 Feb;94:106265. doi: 10.1016/j.msard.2025.106265. Epub 2025 Jan 10. Mult Scler Relat Disord. 2025. PMID: 39827539
-
A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson's disease.Front Neurol. 2023 Jun 15;14:1204733. doi: 10.3389/fneur.2023.1204733. eCollection 2023. Front Neurol. 2023. PMID: 37396780 Free PMC article.
-
Eye movement deficits in Multiple Sclerosis: Characterizing executive problems as the disease worsens.Mult Scler Relat Disord. 2025 Mar;95:106333. doi: 10.1016/j.msard.2025.106333. Epub 2025 Feb 12. Mult Scler Relat Disord. 2025. PMID: 39970865
-
Abnormal eye movements in Parkinson's disease: From experimental study to clinical application.Parkinsonism Relat Disord. 2023 Oct;115:105791. doi: 10.1016/j.parkreldis.2023.105791. Epub 2023 Jul 29. Parkinsonism Relat Disord. 2023. PMID: 37537120 Review.
-
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.Mult Scler. 2002 Oct;8(5):359-65. doi: 10.1191/1352458502ms845oa. Mult Scler. 2002. PMID: 12356200 Review.
Cited by
-
Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking study.Mult Scler J Exp Transl Clin. 2024 May 29;10(2):20552173241255008. doi: 10.1177/20552173241255008. eCollection 2024 Apr-Jun. Mult Scler J Exp Transl Clin. 2024. PMID: 38817553 Free PMC article.
-
From progression to progress: The future of multiple sclerosis.J Cent Nerv Syst Dis. 2024 May 6;16:11795735241249693. doi: 10.1177/11795735241249693. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38711957 Free PMC article.
-
Eye movement function captured via an electronic tablet informs on cognition and disease severity in Parkinson's disease.Sci Rep. 2024 Apr 20;14(1):9082. doi: 10.1038/s41598-024-59750-9. Sci Rep. 2024. PMID: 38643273 Free PMC article.
-
Eye-Tracking Metrics as a Digital Biomarker for Neurocognitive Disorders in Multiple Sclerosis: A Scoping Review.Brain Sci. 2025 Jan 31;15(2):149. doi: 10.3390/brainsci15020149. Brain Sci. 2025. PMID: 40002482 Free PMC article. Review.
-
Development of oculomotor digital biomarkers using clinical examinations as "Ground Truth".Front Hum Neurosci. 2025 May 21;19:1556451. doi: 10.3389/fnhum.2025.1556451. eCollection 2025. Front Hum Neurosci. 2025. PMID: 40469095 Free PMC article.
References
-
- Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, et al. . International advisory committee on clinical trials in multiple sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. (2023) 22:78–88. doi: 10.1016/S1474-4422(22)00289-7 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources